ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:00AM-10:15AM: Abstract Number: 1728

Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study

Abstracts: Immunological Complications of Medical Therapy (1728–1733)

10:00AM-10:15AM: Abstract Number: 1752

Prg4+ Ligament Cells Are Involved in Ligament Ossification in Ankylosing Spondylitis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1752–1757)

10:00AM-10:15AM: Abstract Number: 1758

Treg need a MAIT: Investigating the contribution of MAIT cells to impaired UV-induced Treg expansion in lupus photosensitive reactions

Abstracts: Systemic Lupus Erythematosus – Animal Models (1758–1763)

10:15AM-10:30AM: Abstract Number: 1753

Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1752–1757)

10:15AM-10:30AM: Abstract Number: 1741

Chronic JDM Plasma Proteomic Signature Reflects Inflammation from Immune and Tissue-resident Muscle and Skin

Abstracts: Pediatric Rheumatology – Clinical II (1740–1745)

10:15AM-10:30AM: Abstract Number: 1735

Endocrine Disruptors Exacerbates Osteoarthritis Pain And Inflammation

Abstracts: Osteoarthritis & Joint Biology – Basic Science (1734–1739)

10:15AM-10:30AM: Abstract Number: 1765

Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial

Abstracts: Vasculitis – ANCA-Associated (1764–1769)

10:15AM-10:30AM: Abstract Number: 1747

Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes I: Breathe (ILD/Pulmonary) (1746–1751)

10:15AM-10:30AM: Abstract Number: 1759

Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.

Abstracts: Systemic Lupus Erythematosus – Animal Models (1758–1763)

10:15AM-10:30AM: Abstract Number: 1729

The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy

Abstracts: Immunological Complications of Medical Therapy (1728–1733)

10:30AM-12:30PM: Abstract Number: 1956

68Ga-FAPI-04 and 18F-FDG PET/ CT in MDA5 dermatomyositis-associated interstitial lung disease: a single-center, pilot study

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 2054

A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-Center Cohort

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2389

A Comparison of Patients with Older Onset vs. Younger Onset SLE: A Retrospective Cohort Study

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2519

A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan

(2504–2523) Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 1936

A Fully Automated Method for Measuring Minimum Tibiofemoral Joint Space Width in Knee Osteoarthritis Assessment: Data from the FNIH cohort

(1936–1971) Imaging of Rheumatic Diseases Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].